Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice.

Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG.

Gene Ther. 2008 Jan;15(1):61-4. Epub 2007 Nov 1.

2.

Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.

Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG.

J Immunol. 2007 Jan 1;178(1):566-73.

3.

Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.

Moeini S, Saeidi M, Fotouhi F, Mondanizadeh M, Shirian S, Mohebi A, Gorji A, Ghaemi A.

Arch Virol. 2017 Feb;162(2):333-346. doi: 10.1007/s00705-016-3091-5. Epub 2016 Oct 3. Erratum in: Arch Virol. 2017 Feb;162(2):347.

PMID:
27699512
4.

Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.

Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, Agadjanyan MG.

J Cell Biochem. 2006 Aug 1;98(5):1037-43.

PMID:
16741971
5.
6.

Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies.

Kim TW, Hung CF, Boyd D, Juang J, He L, Kim JW, Hardwick JM, Wu TC.

J Immunol. 2003 Sep 15;171(6):2970-6.

7.

Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.

Tian S, Liu Z, Donahue C, Falo LD Jr, You Z.

Mol Ther. 2012 Feb;20(2):432-42. doi: 10.1038/mt.2011.183. Epub 2011 Sep 20.

8.

Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.

Cecil DL, Holt GE, Park KH, Gad E, Rastetter L, Childs J, Higgins D, Disis ML.

Cancer Res. 2014 May 15;74(10):2710-8. doi: 10.1158/0008-5472.CAN-13-3286. Epub 2014 Apr 28.

9.

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.

PMID:
21668311
10.

A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.

Snyder LA, Goletz TJ, Gunn GR, Shi FF, Harris MC, Cochlin K, McCauley C, McCarthy SG, Branigan PJ, Knight DM.

Vaccine. 2006 Apr 12;24(16):3340-52. Epub 2006 Jan 19.

PMID:
16472547
11.

Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.

Rosato A, Zoso A, Milan G, Macino B, Dalla Santa S, Tosello V, Di Carlo E, Musiani P, Whalen RG, Zanovello P.

J Immunol. 2003 Nov 15;171(10):5172-9.

12.

Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.

Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J.

J Immunol. 2005 May 15;174(10):6292-8.

13.

Improvement in T helper 1-related immune responses in BALB/c mice immunized with an HIV-1 gag plasmid combined with a chimeric plasmid encoding interleukin-18 and flagellin.

Chen YL, Chen YS, Hung YC, Liu PJ, Tasi HY, Ni WF, Hseuh PT, Lin HH.

Microbiol Immunol. 2015 Aug;59(8):483-94. doi: 10.1111/1348-0421.12274.

14.

Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.

Tian H, Shi G, Yang G, Zhang J, Li Y, Du T, Wang J, Xu F, Cheng L, Zhang X, Dai L, Chen X, Zhang S, Yang Y, Yu D, Wei Y, Deng H.

BMC Cancer. 2014 Jan 29;14:48. doi: 10.1186/1471-2407-14-48.

15.

Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.

Mkrtichyan M, Ghochikyan A, Davtyan H, Movsesyan N, Loukinov D, Lobanenkov V, Cribbs DH, Laust AK, Nelson EL, Agadjanyan MG.

Cell Immunol. 2011;270(2):188-97. doi: 10.1016/j.cellimm.2011.05.007. Epub 2011 May 12.

16.

Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice.

Cui FD, Asada H, Jin ML, Kishida T, Shin-Ya M, Nakaya T, Kita M, Ishii M, Iwai M, Okanoue T, Imanishi J, Mazda O.

Gene Ther. 2005 Jan;12(2):160-8.

PMID:
15470476
17.

Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.

de Jesus Pereira NC, Régis WC, Costa LE, de Oliveira JS, da Silva AG, Martins VT, Duarte MC, de Souza JR, Lage PS, Schneider MS, Melo MN, Soto M, Soares SA, Tavares CA, Chávez-Fumagalli MA, Coelho EA.

Exp Parasitol. 2015 Jun;153:180-90. doi: 10.1016/j.exppara.2015.03.027. Epub 2015 Apr 3.

PMID:
25845753
18.

Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants.

Ohlschläger P, Quetting M, Alvarez G, Dürst M, Gissmann L, Kaufmann AM.

Int J Cancer. 2009 Jul 1;125(1):189-98. doi: 10.1002/ijc.24333.

19.

Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein.

Lazdina U, Hultgren C, Frelin L, Chen M, Lodin K, Weiland O, Leroux-Roels G, Quiroga JA, Peterson DL, Milich DR, Sällberg M.

J Gen Virol. 2001 Jun;82(Pt 6):1299-308.

PMID:
11369873
20.

Protective immune response against Toxoplasma gondii elicited by a recombinant DNA vaccine with a novel genetic adjuvant.

Zhou H, Min J, Zhao Q, Gu Q, Cong H, Li Y, He S.

Vaccine. 2012 Feb 27;30(10):1800-6. doi: 10.1016/j.vaccine.2012.01.004. Epub 2012 Jan 10.

PMID:
22240340

Supplemental Content

Support Center